{"id":"https://openalex.org/W2127051533","doi":"https://doi.org/10.1158/1078-0432.ccr-13-2846","title":"Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts","display_name":"Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts","alternate_titles":[],"publication_year":2014,"publication_date":"2014-07-14","ids":{"openalex":"https://openalex.org/W2127051533","doi":"https://doi.org/10.1158/1078-0432.ccr-13-2846","mag":"2127051533","pmid":"https://pubmed.ncbi.nlm.nih.gov/24850847"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-13-2846","doi":"https://doi.org/10.1158/1078-0432.ccr-13-2846","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-13-2846","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3763/2020057/3763.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2127051533"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3763/2020057/3763.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034542306","display_name":"Sonya C. Tate","orcid":"https://orcid.org/0000-0002-6453-2749","observed_orcids":["https://orcid.org/0000-0002-6453-2749"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Sonya C. Tate","raw_affiliation_strings":["Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]},{"raw_affiliation_string":"Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shufen Cai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shufen Cai","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079629521","display_name":"Rose T. Ajamie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rose T. Ajamie","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112231298","display_name":"Teresa F. Burke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Teresa Burke","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109124374","display_name":"Richard Paul Beckmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Richard P. Beckmann","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083329029","display_name":"Edward Michael Chan","orcid":"https://orcid.org/0000-0002-1332-2987","observed_orcids":["https://orcid.org/0000-0002-1332-2987"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edward M. Chan","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055899487","display_name":"Alfonso de Dios","orcid":"https://orcid.org/0009-0004-1639-9121","observed_orcids":["https://orcid.org/0009-0004-1639-9121"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alfonso De Dios","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022761123","display_name":"Graham N. Wishart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Graham N. Wishart","raw_affiliation_strings":["Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]},{"raw_affiliation_string":"Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065087121","display_name":"Lawrence M. Gelbert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lawrence M. Gelbert","raw_affiliation_strings":["2Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049306094","display_name":"Damien M. Cronier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Damien M. Cronier","raw_affiliation_strings":["Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]},{"raw_affiliation_string":"Authors' Affiliations: Eli Lilly and Company, Windlesham, United Kingdom; and","institution_ids":["https://openalex.org/I4210095227"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034542306"],"corresponding_institution_ids":["https://openalex.org/I4210095227"],"apc_list":null,"apc_paid":null,"fwci":6.6863,"has_fulltext":true,"cited_by_count":141,"citation_normalized_percentile":{"value":0.98105056,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"20","issue":"14","first_page":"3763","last_page":"3774"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.6958000063896179,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.6958000063896179,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11829","display_name":"Mathematical Biology Tumor Growth","score":0.14710000157356262,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.03020000085234642,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9399999976158142},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.8429999947547913},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.847000002861023},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.9279999732971191},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.8270000219345093},{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.9760000109672546},{"id":"https://openalex.org/keywords/phosphohistone-h3","display_name":"phosphohistone H3","score":0.9750000238418579},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.527999997138977},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6880000233650208}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6154801845550537},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5931110978126526},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.5526071190834045},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5393732190132141},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.5252208709716797},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.5000162124633789},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.46509850025177},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.46389392018318176},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46275708079338074},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.43071994185447693},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4306226670742035},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37908899784088135},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35575437545776367},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3136219382286072},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.21118921041488647},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18326035141944885},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08648958802223206}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020128","descriptor_name":"Inhibitory Concentration 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047368","descriptor_name":"Tumor Burden","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D051358","descriptor_name":"Cyclin-Dependent Kinase 4","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051361","descriptor_name":"Cyclin-Dependent Kinase 6","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-13-2846","doi":"https://doi.org/10.1158/1078-0432.ccr-13-2846","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-13-2846","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3763/2020057/3763.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:24850847","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24850847","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.ccr-13-2846","doi":"https://doi.org/10.1158/1078-0432.ccr-13-2846","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-13-2846","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3763/2020057/3763.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2127051533.pdf","grobid_xml":"https://content.openalex.org/works/W2127051533.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W31572314","https://openalex.org/W1832188863","https://openalex.org/W1868383104","https://openalex.org/W1899532244","https://openalex.org/W1983635800","https://openalex.org/W2007112340","https://openalex.org/W2020099088","https://openalex.org/W2023437767","https://openalex.org/W2026106245","https://openalex.org/W2030070078","https://openalex.org/W2034269086","https://openalex.org/W2039028514","https://openalex.org/W2043352208","https://openalex.org/W2043761487","https://openalex.org/W2044348066","https://openalex.org/W2059722081","https://openalex.org/W2066980099","https://openalex.org/W2074642772","https://openalex.org/W2080571938","https://openalex.org/W2091722004","https://openalex.org/W2099742439","https://openalex.org/W2102921180","https://openalex.org/W2125110978","https://openalex.org/W2128016549","https://openalex.org/W2135220644","https://openalex.org/W2136158663","https://openalex.org/W2148090903","https://openalex.org/W2149139293","https://openalex.org/W2152616419","https://openalex.org/W2154626333","https://openalex.org/W2172249054","https://openalex.org/W3011926296"],"related_works":["https://openalex.org/W2020099088","https://openalex.org/W2080571938","https://openalex.org/W3011926296","https://openalex.org/W1991601194","https://openalex.org/W7207158274","https://openalex.org/W2154626333","https://openalex.org/W2132726386","https://openalex.org/W7203921677","https://openalex.org/W4251423607","https://openalex.org/W2109344679"],"abstract_inverted_index":{"PURPOSE:":[0],"Selective":[1],"inhibition":[2,64,99],"of":[3,19,31,47,106,177,210],"cyclin-dependent":[4],"kinases":[5],"4":[6],"and":[7,65,81,113,123,153,157,188,212,217],"6":[8],"(CDK4/6)":[9],"represents":[10],"a":[11,49,85,116,167],"promising":[12],"therapeutic":[13,215],"strategy.":[14],"However,":[15],"despite":[16],"documented":[17],"evidence":[18],"clinical":[20,224],"activity,":[21],"limited":[22],"information":[23],"is":[24,180],"available":[25],"on":[26],"the":[27,44,75,104,207,214],"optimal":[28],"dosing":[29,169,219],"strategy":[30,170,220],"CDK4/6":[32,50,63,149],"inhibitors.":[33],"Here,":[34],"we":[35],"present":[36],"an":[37],"integrated":[38],"semi-mechanistic":[39],"pharmacokinetic/pharmacodynamic":[40],"model":[41,92,145,163,202],"to":[42,62,96,109,182],"characterize":[43],"quantitative":[45,208],"pharmacology":[46,209],"LY2835219,":[48],"inhibitor,":[51],"in":[52,68,138,155,160,223],"xenograft":[53],"tumors.":[54],"EXPERIMENTAL":[55],"DESIGN:":[56],"LY2835219":[57,197,211],"plasma":[58,175,198],"concentrations":[59,176],"were":[60],"connected":[61,95],"cell-cycle":[66,151,185],"arrest":[67],"colo-205":[69],"human":[70,140],"colorectal":[71],"xenografts":[72],"by":[73,133,194],"incorporating":[74,115],"biomarkers,":[76],"phospho-(ser780)-Rb,":[77],"topoisomerase":[78],"II":[79],"\u03b1,":[80],"phosphohistone":[82],"H3,":[83],"into":[84,206],"precursor-dependent":[86],"transit":[87],"compartment":[88],"model.":[89],"This":[90],"biomarker":[91],"was":[93,131,158],"then":[94],"tumor":[97,107],"growth":[98,108],"(TGI)":[100],"by:":[101],"(i)":[102],"relating":[103],"rate":[105],"mitotic":[110],"cell":[111,124,189],"density,":[112],"(ii)":[114],"concentration-dependent":[117],"mixed":[118],"cytostatic/cytotoxic":[119],"effect":[120,137],"driving":[121],"quiescence":[122],"death":[125,190],"at":[126],"high":[127],"doses.":[128],"Model":[129],"validation":[130],"evaluated":[132],"predicting":[134],"LY2835219-mediated":[135,148],"antitumor":[136],"A375":[139],"melanoma":[141],"xenografts.":[142],"RESULTS:":[143],"The":[144,162],"successfully":[146],"described":[147],"inhibition,":[150],"arrest,":[152],"TGI":[154],"colo-205,":[156],"validated":[159],"A375.":[161],"also":[164],"demonstrated":[165],"that":[166],"chronic":[168,218],"achieving":[171],"minimum":[172],"steady-state":[173],"trough":[174],"200":[178],"ng/mL":[179],"required":[181],"maintain":[183],"durable":[184],"arrest.":[186],"Quiescence":[187],"can":[191],"be":[192],"induced":[193],"further":[195],"increasing":[196],"concentrations.":[199],"CONCLUSIONS:":[200],"Our":[201],"provides":[203],"mechanistic":[204],"insight":[205],"supports":[213],"dose":[216],"currently":[221],"adopted":[222],"studies.":[225]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2127051533","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":19},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":18},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":15},{"year":2015,"cited_by_count":16},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
